ABSTRACT
Objective: To systematically evaluate the effect of hepatitis B virus (HBV) infection on the risk of adverse pregnancy outcomes. Methods: We searched PubMed, Embase, Web of Science, and Cochrane databases. Two researchers independently screened the literature, extracted data, and evaluated the quality. Meta-analysis and cumulative meta-analysis were performed using R4.4.1 software. Fixed/random effects models were used to analyze heterogeneous and non-heterogeneous results. Heterogeneous modifiers were identified by subgroup analysis. Funnel plots and Peters' test were used to analyze potential publication bias. Results: A total of 48 studies involving 92 836 HBsAg-positive pregnant women and 7 123 292 HBsAg-negative pregnant women were included. In terms of adverse pregnancy outcomes, HBV infection was significantly correlated with the occurrence of gestational diabetes mellitus [odds ratio (OR)=1.34, 95% confidence interval (CI): 1.17-1.53] and intrahepatic cholestasis (OR=2.48, 95%CI: 1.88-3.29), with statistically significant differences. In terms of adverse neonatal outcomes, HBV infection was significantly correlated with the occurrence of neonatal asphyxia (OR=1.49, 95%CI: 1.20-1.86) and preterm birth (OR=1.22, 95%CI: 1.12-1.33), with statistically significant differences. In addition, the cumulative meta-analysis demonstrated that the risk of gestational diabetes mellitus and preterm birth both tended to be stable in pregnant women with HBV infection following 2009 and 2010, respectively. The supplementary questions answered for repeated studies had limited significance. Conclusion: Intrahepatic cholestasis, gestational diabetes mellitus, neonatal asphyxia, and preterm birth occurrence risk can be raised with HBV infection in pregnant women.
Subject(s)
Hepatitis B , Pregnancy Complications, Infectious , Pregnancy Outcome , Humans , Pregnancy , Female , Hepatitis B/epidemiology , Hepatitis B/complications , Pregnancy Complications, Infectious/virology , Pregnancy Complications, Infectious/epidemiology , Hepatitis B virus , Diabetes, Gestational/epidemiology , Premature Birth/epidemiology , Infant, Newborn , Cholestasis, Intrahepatic/epidemiology , Risk FactorsABSTRACT
BACKGROUND: What kinds of fetal adverse outcomes beyond stillbirth directly correlate to the severity of intrahepatic cholestasis during pregnancy (ICP) remained tangled. Herein, we conducted a retrospective cohort study and a dose-response meta-analysis to speculate the association between the severity of ICP and its adverse outcomes. METHODS: We retrospectively collected a cohort of ICP patients from electronic records from Guangzhou Women and Children's Medical Center between Jan 1st, 2018, and Dec 31st, 2022. Also, we searched PubMed, Cochrane, Embase, Scopus, and Web of Science to extract prior studies for meta-analysis. The Kruskal-Wallis test, a one-way or two-way variants analysis (ANOVA), and multi-variant regression are utilized for cohort study. One stage model, restricted cubic spline analysis, and fixed-effect model are applied for dose-response meta-analysis. The data analysis was performed using the R programme. RESULTS: Our cohort included 1,289 pregnant individuals, including 385 mild ICP cases, 601 low moderate ICP cases, 282 high moderate ICP cases, and 21 severe ICP cases. The high moderate bile acid levels were correlated to preterm birth [RR = 2.14, 95%CI 1.27 to 3.62), P < 0.01], and preterm premature rupture of membranes [RR = 0.34, 95%CI 0.19 to 0.62), P < 0.01]. We added our cases to cases reported by other studies included in the meta-analysis. There were 15,826 patients included in dose-response meta-analysis. The severity of ICP was associated with increased risks of stillbirth, spontaneous preterm birth, iatrogenic preterm birth, preterm birth, admission to neonatal intensive care unit, and meconium-stained fluid (P < 0.05). CONCLUSIONS: Our study shows the correlation between the severity of ICP and the ascending risks of stillbirth, preterm birth, and meconium-stained fluid, providing new threshold TBA levels. PROSPERO REGISTRATION NUMBER: CRD42023472634.
Subject(s)
Cholestasis, Intrahepatic , Pregnancy Complications , Premature Birth , Severity of Illness Index , Stillbirth , Humans , Cholestasis, Intrahepatic/epidemiology , Cholestasis, Intrahepatic/complications , Female , Pregnancy , Pregnancy Complications/epidemiology , Retrospective Studies , Stillbirth/epidemiology , Adult , Premature Birth/epidemiology , Infant, Newborn , China/epidemiology , Pregnancy Outcome/epidemiology , Fetal Membranes, Premature Rupture/epidemiology , Risk FactorsABSTRACT
BACKGROUND: Intrahepatic cholestasis of pregnancy (ICP) is associated with an increased risk of adverse fetal outcomes, yet its influence on offspring growth remains unclear. Our study dynamically tracks growth rates in children from ICP and healthy mothers and investigates the link between maternal liver function and developmental abnormalities in offspring. METHOD: Our caseâcontrol study involved 97 women with ICP and 152 with uncomplicated pregnancies nested in a cohort of their offspring, including 50 from the ICP group and 87 from the uncomplicated pregnancy group. We collected pediatric growth and development data, with a maximum follow-up duration of 36 months. Stratified analyses of children's height, weight, and head circumference were conducted, and Spearman's rank correlation was applied to examine the relationships between maternal serological markers and pediatric growth metrics. RESULT: Maternal liver and renal functions, along with serum lipid profiles, significantly differed between the ICP and normal groups. In the ICP group, the offspring showed elevated alanine aminotransferase (ALT), direct bilirubin (DBIT), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein B (APOB) levels. Notably, the length-for-age z score (LAZ), weight-for-age z score (WAZ), and head circumference-for-age z score (HCZ) were lower in ICP offspring compared with those from normal pregnancies within the 1- to 12-month age range (P < 0.05). However, no significant differences in LAZ, weight-for-length z score (WLZ), BMI-for-age z score (BAZ), or HCZ were observed between groups in the 13- to 36-month age range. Maternal maximum lactate dehydrogenase (LDH) and total bile acids (TBA) levels during pregnancy were inversely correlated with LAZ and WAZ in the first year. Furthermore, offspring of mothers with ICP exhibited a greater incidence of stunting (24% vs. 6.9%, P = 0.004) and abnormal HCZ (14% vs. 3.7%, P = 0.034). CONCLUSIONS: Growth disparities in offspring of ICP-affected pregnancies were most significant within the 1- to 12-month age range. During this period, maximum maternal LDH and TBA levels were negatively correlated with LAZ and WAZ values of offspring. The observation of similar growth rates between ICP and control group offspring from 13 to 36 months suggested catch-up growth in the ICP group.
Subject(s)
Cholestasis, Intrahepatic , Pregnancy Complications , Humans , Female , Cholestasis, Intrahepatic/blood , Cholestasis, Intrahepatic/epidemiology , Pregnancy , Pregnancy Complications/blood , Pregnancy Complications/epidemiology , Case-Control Studies , Adult , Child Development/physiology , Child, Preschool , Prenatal Exposure Delayed Effects , Infant , Cohort Studies , Alanine Transaminase/blood , Body Height , Male , Bilirubin/blood , Liver Function TestsABSTRACT
OBJECTIVE: To explore the relationships between gestational hepatitis B virus (HBV) infection, antiviral therapy, and pregnancy outcomes. METHODS: We retrospectively selected hepatitis B surface antigen (HBsAg)-positive pregnant women hospitalized for delivery at Fujian Medical University Affiliated Hospital from October 1, 2016 to October 1, 2020. The control group included randomly selected healthy pregnant women hospitalized for delivery during the same time. RESULTS: Overall, 1115 participants were enrolled and grouped into control (n = 380) and HBsAg-positive groups (n = 735), which were further divided into groups I (n = 407; low viral load), II (n = 207; high viral load without antiviral therapy), and III (n = 121; high viral load with antiviral therapy). Pregnant women with HBV were positively correlated with the incidence of intrahepatic cholestasis of pregnancy (ICP) (adjusted odds ratio [aOR] 5.1, 95% confidence interval [CI] 2.62-9.92, P < 0.001), neonatal jaundice (aOR 10.56, 95% CI 4.49-24.83, P < 0.001), and neonatal asphyxia (aOR 5.03, 95% CI 1.46-17.27, P = 0.01). Aspartate aminotransferase (AST) greater than the upper limit of normal (ULN) was an independent risk factor for increased ICP incidence (aOR 3.49, 95% CI 1.26-9.67, P = 0.019). Antiviral therapy considerably reduced HBV DNA and improved liver function. High viral load and antiviral therapy did not correlate significantly with adverse pregnancy outcomes (P < 0.05). CONCLUSION: Pregnant women with HBV have significantly elevated incidence of ICP, neonatal jaundice, and neonatal asphyxia not significantly correlated with viral load. AST greater than ULN independently increases the risk of ICP. Antiviral therapy effectively reduces viral replication and improves liver function without increasing the risk of adverse outcomes.
Subject(s)
Antiviral Agents , Hepatitis B , Pregnancy Complications, Infectious , Pregnancy Outcome , Viral Load , Humans , Female , Pregnancy , Retrospective Studies , Antiviral Agents/therapeutic use , Pregnancy Complications, Infectious/drug therapy , Pregnancy Complications, Infectious/virology , Adult , Hepatitis B/epidemiology , Hepatitis B/drug therapy , Cholestasis, Intrahepatic/epidemiology , China/epidemiology , Hepatitis B Surface Antigens/blood , Hepatitis B virus , Infant, Newborn , Case-Control Studies , Jaundice, Neonatal/epidemiology , Pregnancy ComplicationsABSTRACT
BACKGROUND: Intrahepatic cholestasis of pregnancy (ICP) is a serious liver conditions that negatively impacts obstetric and neonatal outcomes. Elevated levels of bile acid, particularly glycine conjugate, may compromise blood flow and cause functional hypoxia-ischemia. AIMS: This meta-analysis aims to assess the association between ICP and key pregnancy outcomes including emergency caesarian sections (C-sections), preeclampsia, hemorrhage, preterm birth, small for gestational age, admission rate to neonatal intensive care union (NICU), gestational age, and stillbirth. MATERIALS AND METHODS: Literature search across five databases (PubMed, Embase, Web of Science) was done to detect relevant studies published up until June 2023. Meta-analysis of the identified studies was done using a random-effects model, and the results presented as Odds ratio (OR). RESULTS: A literature search identified 662 studies. Of them, 21 met the inclusion criteria. There was a significant association between ICP and odds of C-section (OR: 1.42, p <0.001), preeclampsia (OR: 2.64, p <0.001), NICU admission (OR: 2.1, p <0.001), and pre-term birth (OR: 2.64, p <0.001). ICP was not associated with postpartum hemmorhage (OR: 1.31, p = 0.13), small for gestational age (OR: 0.87, p = 0.07), stillbirth (OR: 1.49, p = 0.29). CONCLUSIONS: Our results confirm the adverse effects of ICP on co-existing pregnancy complications, obstetric and neonatal outcomes. ICP in associated with severe complications including increased rates of preeclampsia, emergency C-sections, preterm births, l gestational periods and higher rates of NICU admissions. These results may assist healthcare professionals in formulating comprehensive care guidelines for expectant mothers and newborns.
Subject(s)
Cholestasis, Intrahepatic , Pregnancy Complications , Pregnancy Outcome , Premature Birth , Humans , Pregnancy , Cholestasis, Intrahepatic/complications , Cholestasis, Intrahepatic/epidemiology , Female , Pregnancy Complications/epidemiology , Infant, Newborn , Premature Birth/epidemiology , Stillbirth/epidemiology , Pre-Eclampsia/epidemiology , Cesarean Section , Gestational Age , Infant, Small for Gestational AgeABSTRACT
INTRODUCTION: Intrahepatic cholestasis of pregnancy (ICP) is a problem with an increasing incidence and negative maternal, fetal, and neonatal consequences. This problem is becoming increasingly important. This systematic review and meta-analysis aimed to determine the incidence of ICP and its adverse maternal, fetal, and neonatal adverse outcomes based on primary research studies. METHODS: This systematic review and meta-analysis used Preferred Reporting Items for Systematic Reviews and Meta-Analyses reporting guidelines and was conducted between June and September 2023 using the following keywords: obstetric cholestasis OR intrahepatic cholestasis AND pregnancy OR pregnant OR prenatal OR antenatal OR perinatal OR maternal OR fetal OR neonatal. Quality assessment of the studies was performed using the Critical Appraisal Checklists developed by the JBI Institute. Data were synthesized using meta-analysis methods. RESULTS: The analysis included 10 studies published between 2013 and 2023. The meta-analysis showed that the incidence of ICP was 1.7% (odds ratio [OR], 0.021; 95% CI, 0.012-0.027), whereas maternal, fetal, and neonatal adverse outcomes included cesarean birth (OR, 2.938; 95% CI, 1.467-5.881), preterm birth or preterm prelabor rupture of membranes (OR, 4.241; 95% CI, 1.996-9.009), hypertensive disorders of pregnancy (OR, 3.715; 95% CI, 1.545-8.929), maternal infection (OR, 3.301; 95% CI, 2.917-3.737), neonatal intensive care unit admission (OR, 2.715; 95% CI, 1.458-5.056), birth weight less than or equal to 2500 g (OR, 2.518; 95% CI, 1.296-4.892), and small for gestational age (OR, 1.915; 95% CI, 1.424-2.573). DISCUSSION: This systematic review and meta-analysis revealed that ICP has a high incidence and several maternal, fetal, and neonatal adverse outcomes. Therefore, midwives and other health professionals must be aware of these outcomes and provide appropriate care to pregnant individuals with ICP.
Subject(s)
Cholestasis, Intrahepatic , Pregnancy Complications , Pregnancy Outcome , Humans , Pregnancy , Cholestasis, Intrahepatic/epidemiology , Female , Pregnancy Complications/epidemiology , Infant, Newborn , Incidence , Pregnancy Outcome/epidemiology , Premature Birth/epidemiology , Cesarean Section/statistics & numerical dataABSTRACT
Background and Objectives: Intrahepatic cholestasis of pregnancy (ICP) stands as one of the most prevalent concerns in maternal-fetal medicine, presenting a significant risk to fetal health and often associated with liver dysfunction. Concurrently, the coronavirus-19 (COVID-19) infection can lead to hepatic cell injury through both direct and indirect pathways. Hypothetically, these two conditions may coincide, influencing each other. This study aimed to comparatively assess the incidence and severity of ICP before and during the COVID-19 pandemic. Methods: A retrospective cohort study was conducted, comparing the incidence and severity of ICP between January 2018 and February 2020 (pre-COVID-19 period) and March 2020 to March 2022 (COVID-19 period) across two hospitals, encompassing 7799 deliveries. The diagnosis of ICP was established using the ICD-10 code and defined as total bile acids (BA) levels ≥ 10 µmol/L. Statistical analysis included descriptive statistics, Chi-square and Mann-Whitney U tests, as well as multiple or logistic regression analysis. Results: A total of 226 cases of ICP were identified. The incidence of mild cholestasis (BA < 40 µmol/L) was lower during the pandemic compared to before (3% before versus 2%, p < 0.05), while the incidence of moderate and severe ICP remained unchanged (0.6% before vs. 0.4%, p = 0.2). Overall, the total incidence of ICP was lower during the pandemic (3.6% before versus 2.4%, p = 0.01). No significant differences were observed in severity (as defined by BA and liver function test levels), rates of caesarean section, or neonatal birth weights. Conclusions: During the COVID-19 pandemic, the total incidence of ICP appeared to be lower. However, this reduction was primarily observed in cases of mild ICP, potentially indicating challenges in detection or reduced access to medical services during this period. The incidence of moderate and severe ICP remained unchanged, suggesting that these forms of the condition were unaffected by the pandemic's circumstances.
Subject(s)
COVID-19 , Cholestasis, Intrahepatic , Pregnancy Complications , Humans , Female , Cholestasis, Intrahepatic/epidemiology , Pregnancy , COVID-19/epidemiology , Retrospective Studies , Pregnancy Complications/epidemiology , Adult , Incidence , Pandemics , Severity of Illness Index , SARS-CoV-2ABSTRACT
PURPOSE: To evaluate maternal and neonatal outcomes in patients with intrahepatic cholestasis of pregnancy (ICP). METHODS: Patients who gave birth in our hospital between January 2018 and March 2022 were retrospectively reviewed from the hospital database and patient file records. The study comprised 1686 patients, 54 in the ICP group and 1632 controls. Patients who had ICP after 20 weeks of gestation and were monitored and delivered at our facility were enrolled. Maternal demographic and obstetric characteristics data were examined. Perinatal outcomes were also assessed. Logistic regression analysis was used to determine adverse maternal outcomes. RESULTS: The mean age was 29 years. ART, GDM, and preeclampsia were significantly higher in the ICP group. The mean serum bile acid level was 19.3 ± 3 µmol/L in the ICP group. There was a higher risk of GDM and pre-eclampsia in women with ICP compared with those without and a significant association between ICP and adverse perinatal outcomes. There was a statistically significant relation between the presence of ICP and spontaneous preterm delivery, iatrogenic preterm delivery, 5th-minute Apgar scores < 7, and NICU requirement. No significant relationship was found between the presence of ICP and SGA and meconium. There was a significant relationship between the presence of ICP, mode of delivery, and PPH (p < 0.05). Those with ICP had a lower gestational week and birth weight, and higher rates of cesarean delivery and PPH. CONCLUSION: ICP should prompt close monitoring and management to mitigate the potential exacerbation of adverse outcomes, including preeclampsia, GDM, and preterm birth.
Subject(s)
Cholestasis, Intrahepatic , Diabetes, Gestational , Pre-Eclampsia , Pregnancy Complications , Humans , Pregnancy , Female , Cholestasis, Intrahepatic/blood , Cholestasis, Intrahepatic/epidemiology , Cholestasis, Intrahepatic/complications , Diabetes, Gestational/epidemiology , Diabetes, Gestational/blood , Retrospective Studies , Adult , Pre-Eclampsia/epidemiology , Pre-Eclampsia/blood , Pregnancy Complications/epidemiology , Pregnancy Complications/blood , Infant, Newborn , Pregnancy Outcome/epidemiology , Premature Birth/epidemiology , Premature Birth/etiology , Case-Control Studies , Apgar Score , Bile Acids and Salts/bloodABSTRACT
BACKGROUND: The association between excessive serum total bile acid (TBA) and adverse perinatal outcomes in individuals with non-intrahepatic cholestasis of pregnancy (non-ICP) hypercholanemia has not been determined, and it is unclear if this link is similar to that observed in patients with ICP. OBJECTIVE: To examine the adverse perinatal outcomes in two specific subcategories: those with ICP and those with non-ICP, including individuals with liver disease and asymptomatic hypercholanemia of pregnancy (AHP), at different levels of TBA. Investigate the correlation between TBA levels and adverse perinatal outcomes of ICP, liver disease, and AHP. METHODS: From 2013 to 2021, pregnant women with excessive TBA levels were taken from the electronic medical record database of our hospital and categorized into three groups: ICP (n = 160), liver disease (n = 164), and AHP (n = 650). This was done as part of a retrospective cohort research project. Multivariable regression and subgroup analyses were performed to examine the association between TBA levels and adverse perinatal outcomes in each group. RESULTS: The study found no significant differences in adverse perinatal outcomes between the ICP and liver disease groups at different TBA levels. However, at moderate TBA levels, both groups had a higher risk of adverse perinatal outcomes than the AHP group (p < 0.017). Among liver disease cases with TBA ≥ 100µmol/L, three cases of perinatal deaths (6.67%) associated with moderate-to-severe acute hepatitis occurred between 27 and 33 weeks of gestation. A 59% higher chance of perinatal death was found for every 10 µmol/L rise in TBA, even after significant variables and confounders were taken into account (adjusted odds ratio (aOR) = 1.59; 95% confidence interval (CI): 1.06-2.40; p = 0.03). CONCLUSIONS: If a pregnant woman has moderate-to-severe liver disease and TBA ≥ 100µmol/L, preterm termination of pregnancy (before 34 weeks) may be considered.
If someone doesn't have ICP but does have moderate-to-severe hepatitis and TBA levels of 100 µmol/L or more, they should be treated more aggressively, and their pregnancies should be terminated earlier (before 34 weeks) than what is usually done for ICP.
Subject(s)
Cholestasis, Intrahepatic , Perinatal Death , Pregnancy Complications , Infant, Newborn , Pregnancy , Female , Humans , Pregnant Women , Bile Acids and Salts , Retrospective Studies , Pregnancy Complications/epidemiology , Cholestasis, Intrahepatic/complications , Cholestasis, Intrahepatic/epidemiologyABSTRACT
Intrahepatic cholestasis of pregnancy (ICP) is an idiopathic disease that occurs during mid-to-late pregnancy and is associated with various adverse pregnancy outcomes, including intrauterine fetal demise. However, since the underlying cause of ICP remains unclear, there is an ongoing debate on the phenotyping criteria used in the diagnostic process. Here, we identified single- and multi-symptomatic ICP (ICP-S and ICP-M) in 104,221 Chinese females from the ZEBRA maternity cohort, with the objective of exploring the risk implications of the two phenotypes on pregnancy outcomes and from environmental exposures. We employed multivariate binary logistic regression to estimate confounder-adjusted odds ratios and found that ICP-M was more strongly associated with preterm birth and low birth weight compared to ICP-S. Throughout pregnancy, incremental exposure to PM2.5, O3, and greenness could alter ICP risks by 17.3%, 12.5%, and -2.3%, respectively, with more substantial associations observed with ICP-M than with ICP-S. The major scientific advancements lie in the elucidation of synergistic risk interactions between pollutants and the protective antagonistic effects of greenness, as well as highlighting the risk impact of preconceptional environmental exposures. Our study, conducted in the context of the "three-child policy" in China, provides epidemiological evidence for policy-making to safeguard maternal and neonatal health.
Subject(s)
Cholestasis, Intrahepatic , Premature Birth , Pregnancy , Infant, Newborn , Female , Humans , Pregnancy Outcome/epidemiology , Cohort Studies , East Asian People , Premature Birth/epidemiology , Environmental Exposure , Cholestasis, Intrahepatic/epidemiology , Cholestasis, Intrahepatic/complicationsSubject(s)
Humans , Female , Pregnancy , Bile Acids and Salts/analysis , Bile Acids and Salts/blood , Cholestasis, Intrahepatic/diagnosis , Cholestasis, Intrahepatic/blood , Cholestasis, Intrahepatic/therapy , Cholestasis, Intrahepatic/epidemiology , Diagnosis, Differential , Fetal Diseases/etiology , Follow-Up Studies , Pregnancy ComplicationsSubject(s)
Humans , Female , Pregnancy , Cholestasis, Intrahepatic/blood , Cholestasis, Intrahepatic/diagnosis , Cholestasis, Intrahepatic/therapy , Bile Acids and Salts/analysis , Bile Acids and Salts/blood , Cholestasis, Intrahepatic/epidemiology , Pregnancy Complications , Diagnosis, Differential , Fetal Diseases/etiology , Follow-Up StudiesABSTRACT
Colestase da gravidez (CG) é uma doença hepática específica da gravidez que tipicamente ocorre a partir do final do segundo trimestre. É uma doença de etiologia heterogênea (multifatorial) com contribuição de fatores genéticos e hormonais, caracterizada por prurido generalizado intenso e alterações das provas de função hepática, estando associada ao aumento das taxas de morbidade e mortalidade fetal. A revisão de literatura realizada refere-se à epidemiologia, etiologia, manifestações clínicas, achados laboratoriais e o manejo da CG na qual se conclui que o conhecimento por parte dos profissionais sobre a doença é fundamental para que seja realizado um manejo adequado das gestantes, visando principalmente prevenir complicações fetais. Apesar do número significativo de estudos relacionados com a CG, vários aspectos da sua etiologia e patogênese não foram elucidados. O diagnóstico é feito por meio de achados clínicos e das alterações das provas de função hepática e aumento dos níveis de ácidos biliares. O ácido ursodesoxicólico é a droga atualmente utilizada na terapêutica da CG com eficácia no controle do prurido e no restabelecimento de níveis normais dos ácidos biliares. Porém, há necessidade da condução de pesquisas e ensaios clínicos para a melhor condução desta doença.
Obstetric cholestasis (OC) is a specific hepatic pathology of the pregnancy that typically happens in the end of the second trimester. It is a heterogeneous etiology (multifactorial) disease with contribution from genetic and hormonal factors, characterized by intense itch and abnormal liver function tests, being associated to the increase of perinatal morbidity and mortality. The revision of accomplished literature refers to the epidemiology, etiology, clinical manifestations, laboratory findings and of which management OC concludes that knowledge by professionals about the disease is the key to an appropriate management, undertaken by pregnant women, seeking mainly to prevent fetal complications. In spite of the significant number of studies related with OC, several aspects of its etiology and pathogenesis were not elucidated. The diagnosis is made through the clinical discoveries and abnormal liver function tests and increase of the levels of bile acids. The ursodeoxycholic acid is now the drug used in the therapeutics of OC with effectiveness in the control of the itch and in the re-establishment of normal levels of the bile acids. However, new research and clinical trials are required for best conduction of this pathology
Subject(s)
Female , Pregnancy , Ursodeoxycholic Acid/therapeutic use , Cholestasis, Intrahepatic/epidemiology , Cholestasis, Intrahepatic/etiology , Cholestasis, Intrahepatic/therapy , Cholestasis/epidemiology , Cholestasis/etiology , Cholestasis/therapy , Pruritus/etiology , Liver Function Tests , Pregnancy Complications/diagnosis , Pregnancy Complications/etiology , Pregnancy Trimester, SecondABSTRACT
Introducción: la toxicidad hepática asociada al uso crecientede productos de remedios naturales es un fenómeno emergente.Objetivos: valoración de las características epidemiológicas,clínicas y demográficas de los casos de hepatotoxicidad secundariosa productos herbales (PH) y suplementos dietéticos(SD).Pacientes y métodos: análisis de los casos de hepatotoxicidaddebida a PH y SD incluidos en el Registro Español de Hepatotoxicidad.Resultados: trece casos de un total de 521 casos (2%) dereacciones adversas hepáticas incluidas en el registro entre1994 y 2006, eran secundarios a PH/SD, representando el décimogrupo terapéutico responsable por orden de frecuencia,por delante de analgésicos, ansiolíticos y antipsicóticos. Nuevepacientes (69%) eran mujeres y la edad media fue de 45 años.Nueve pacientes (69%) presentaron ictericia. El tipo de dañomás frecuente fue el hepatocelular (12; 92%) y un 31% de loscasos presentaron datos de hipersensibilidad. La sustancia máscomúnmente involucrada en los casos de daño hepático fue laCamellia sinensis (23%) seguida de Rhamnus purshianus eisoflavonas (Fitosoja®, Biosoja®) con dos casos cada uno (15%).Tres casos (23%) presentaron re-exposición positiva.Conclusiones: la hepatotoxicidad originada por PH/SD noes excepcional, y su perfil es la hepatitis aguda hepatocelular ictéricapredominantemente en mujeres. La frecuente ocurrenciade reexposición positiva en estos pacientes indica un bajo índicede sospecha y un retraso o ausencia de diagnóstico de estetipo de reacción adversa
Background: toxic liver damage associated with the use ofnatural remedies is a growing health problem.Objectives: to analyze the demographics, and clinical andepidemiological characteristics of patients developing liver injuryrelated to these remedies.Patients and methods: all DILI cases associated with the useof herbal remedies (HR) or dietary supplements (DS) submitted tothe Spanish Registry were analyzed. Type of liver damage, severity,and outcome were specifically evaluated.Results: thirteen cases out of 521 DILI cases (2%) submittedto the Spanish Liver Toxicity Registry between 1994 and2006 were related to HR/DS, which ranked as the 10th therapeuticgroup with a greater number of cases and above painkillers, anxiolytics, and antipsychotic drugs. Nine patients (69%)were female (mean age 45 years). Nine cases (69%) had jaundiceat presentation. The predominating type of liver damagewas hepatocellular (12; 92%), and 31% of cases exhibited thecommon features of hypersensitivity. Camellia sinensis (3,23%) was the main causative herb, followed by Rhamnus purshianusand isoflavones (Fitosoja®, Biosoja®) (2 cases each,15%). Three cases (23%) were rechallenged with the offendingproduct.Conclusions: the incidence of hepatic damage related toHR/DS is not so rare, the most common profile of affected patientsbeing a woman with acute hepatocellular hepatitis. Lowsuspicion regarding the putative role of herbs in hepatotoxicitymakes diagnosis more difficult, and probably increases the incidenceof inadvertent rechallenge in these patients
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Plant Extracts/adverse effects , Chemical and Drug Induced Liver Injury/etiology , Cholestasis, Intrahepatic/chemically induced , Cholestasis, Intrahepatic/epidemiology , Camellia sinensis/adverse effects , Recurrence , Spain/epidemiology , Diseases Registries/statistics & numerical dataABSTRACT
No disponible
Subject(s)
Female , Humans , Pregnancy , Pregnancy , Liver/physiology , Cholestasis, Intrahepatic/diagnosis , Cholestasis, Intrahepatic/epidemiology , Cholestasis, Intrahepatic/drug therapy , Fatty Liver/epidemiology , Pre-Eclampsia , Liver/injuries , Hepatitis A/epidemiology , Hepatitis B/epidemiology , Hepatitis B, Chronic/epidemiology , Hepatitis C/epidemiology , Liver Neoplasms/epidemiology , Cholelithiasis/diagnosis , Cholelithiasis/drug therapy , Cholelithiasis/surgery , Risk Factors , Pregnancy ComplicationsABSTRACT
Se estudian 131 pacientes con colestasia intrahepática del embarazo (CIE) que fueron admitidas en la unidad de feto de alto riesgo (FAR) de la maternidad del Hospital Félix Bulnes en el período de un año (08/96 - 08/97), las mismas que fueron evaluadas y evolucionadas de acuerdo a normas establecidas tanto en la unidad de FAR como durante su hospitalización en la unidad de tratamiento. Se encuentra una frecuencia de CIE de 2.1 por ciento con una mortalidad perinatal del 0 por ciento, se comparan las CIE puras y las con patología asociadas, siendo las más frecuentes anemia, SHE y RCIU, existiendo alto porcentaje de cesárea en este grupo. Se observó que la CIE sin patología asociada no afecta de manera importante las pruebas hepáticas, alteración de la UFP y no influye en el apgar del RN, siendo actualmente considerada una patología menos frecuente y menos grave que antes
Subject(s)
Humans , Female , Pregnancy , Infant, Newborn , Cholestasis, Intrahepatic/epidemiology , Pregnancy Complications , Anemia/complications , Cesarean Section/statistics & numerical data , Cholestasis, Intrahepatic/complications , Pregnancy Outcome/epidemiologyABSTRACT
Se revisan 232 pacientes con colestasis intrahepática del embarazo (CIE) que fueron controladas en el policlínico de Alto Riesgo Obstétrico de la Maternidad del Hospital Las Higueras de Talcahuano durante los años 1993, 1994 y 1995. Se encuentra una frecuencia de la enfermedad del 2,5 por ciento y una Mortalidad perinatal del 4,3 por ciento. Al separar las CIE con y sin patologías asociadas, se produce en las primeras una mayor cantidad de prematurez, recién nacidos de peso bajo, parto por cesárea y mortinatos (p < 0,05). Se compara la evolución de algunos parámetros clínicos de CIE en las tres últimas décadas, encontrándose una franca disminución de ellos
Subject(s)
Humans , Female , Pregnancy , Cholestasis, Intrahepatic/epidemiology , Pregnancy Complications , Prevalence , Cholestasis, Intrahepatic/complications , Cholestasis, Intrahepatic/diagnosis , Cholestasis, Intrahepatic/mortality , Infant Mortality/trends , Parturition/statistics & numerical dataABSTRACT
El objetivo del trabajo fue analizar la vigencia de los criterios de severidad en la CIE y su repercusión en el recién nacido. La muestra de 209 casos corresponde al total de egresos del Servicio de Embarazo Patológico de un Hospital tipo A de Santiago durante 1987. La CIE Severa (59,3%) presentó el Prurito Precoz y la Amenaza de Parto Prematuro como los criterios de severidad más frecuentes. Encontramos que a mayor número de criterios de severidad, peor pronóstico neonatal, objetivado por el peso de nacimiento inferior a 2500 gr y Apgar al minuto menor que 7. No se encontró mortalidad materna ni perinatal. Concluimos que en esta serie los criterios de severidad fueron válidos y que existió un manejo adecuado de la patología, inferido de la ausencia de mortalidad y disminución de la morbilidad materna-perinatal, en relación a estudios anteriores